组蛋白脱乙酰基酶
药理学
化学
药品
食品药品监督管理局
药物发现
异羟肟酸
组蛋白
效力
癌症研究
生物
生物化学
立体化学
基因
体外
作者
Sida Shen,Alan P. Kozikowski
出处
期刊:ChemMedChem
[Wiley]
日期:2015-11-25
卷期号:11 (1): 15-21
被引量:285
标识
DOI:10.1002/cmdc.201500486
摘要
Hydroxamate-based histone deacetylase inhibitors (HDACIs) have been approved as therapeutic agents by the US Food and Drug Administration for use in oncology applications. While the potential utility of such HDACIs in other areas of medicinal chemistry is tremendous, there are significant concerns that "pan-HDAC inhibitors" may be too broadly acting and/or toxic for clinical use beyond oncology. In addition to the isozyme selectivity challenge, the potential mutagenicity of hydroxamate-containing HDAC inhibitors represents a major hindrance in their application to other therapeutic areas. Herein we report on the mutagenicity of known hydroxamates, discuss the mechanisms responsible for their genotoxicity, and review some of the current alternatives to hydroxamates. We conclude that the hydroxamate group, while providing high-potency HDACIs, is not necessarily the best zinc-binding group for HDACI drug discovery.
科研通智能强力驱动
Strongly Powered by AbleSci AI